Angelman Syndrome Clinical Trial
Official title:
Study of the Prevalence of Autistic Traits in Angelman Syndrome, the Correlation With Cognitive Level, Epilepsy, With Socio-communication Skills and Parenting Styles
NCT number | NCT06337383 |
Other study ID # | 12.2021 ANGELMAN |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 15, 2022 |
Est. completion date | June 2024 |
The goal of this observational cross-sectional study is to establish the prevalence of autism spectrum disorder in children and adolescents with Angelman syndrome. The main questions it aims to answer are: - which clinical variables differentiate AS patients with and without Autism Spectrum Disorder between genetics, epilepsy, pharmacotherapy, behavioural problems, parenting style and parents' perceived stress. - which clinical variables differentiate parenting styles and levels of perceived stress. Data from neuropsychological, speech therapy and physiotherapeutic assessments are collected during regular clinical follow-ups, regarding: cognitive development ("Bayely Scales of Infant Development-III", Cognitive Scale) and adaptive behaviour; Autism and Autism Spectrum Disorder ("Autism Diagnostic Observational Schedule-2"); parental stress and parenting styles; social-communicative skills; motor development.
Status | Recruiting |
Enrollment | 46 |
Est. completion date | June 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Years to 14 Years |
Eligibility | Inclusion Criteria: - genetically confirmed diagnosis of Angelman Syndrome - chronological age between 4-15 years Exclusion Criteria: - genetic examination pending report - mental age lower than 12 months - brain injury acquired in the peri- or postnatal period |
Country | Name | City | State |
---|---|---|---|
Italy | I.R.C.C.S. "E.Medea" | Conegliano | Treviso |
Lead Sponsor | Collaborator |
---|---|
IRCCS Eugenio Medea |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total score of the Autism Diagnostic Observation Schedule -2 (ADOS-2), Module 1, | The ADOS-2 consists of different semi-structured standard situations that induce communication, social interaction and imaginative play and that is considered a gold standard in autism assessment; Module 1, that does not require the use of speech, is employed.
In particular, our outcome of interest is the "Total score", given by the sum of the "Communication and Reciprocal Social Interactions" and the "Stereotyped Behaviors and Restricted Interests" raw scores. Higher scores correspond to a greater presence of autistic features (min:0; max:28; cut-off for autism spectrum disorder:11; cut-off for autism disorder:16). |
Once at recruitment | |
Secondary | Age-equivalent score at the Cognitive Scale of the Bayley Scales of Infant Development - 3rd version (Bayley-III) | The Bayley-III Cognitive Scale is used to assess cognitive level. In particular, age-equivalent scores are considered (min: 1 months; max: 42 months). | Once at recruitment | |
Secondary | Total Stress score at the Parent Stress Index - 4th edition (PSI-4) questionnaire | PSI-4 is a standardised parent self-report instrument to explore perceived stress in their role and therefore to identify situations at risk of dysfunctional parent-child system. It is composed of two subscales: the child domain, that identifies six child characteristics, and the parent domain, that describes seven stressors related to parent and family characteristics. Our outcome of interest is the Total Stress score, given by the sum of the scores obtained at the "Child domain" and the "Parent domain".
Higher scores correspond to a greater level of parental stress. |
Once at recruitment | |
Secondary | Global score at the Aberrant Behaviour Checklist (ABC) | The ABC is a questionnaire that measures psychiatric symptoms and behavioural disturbance in individuals with severe or very severe intellectual disability across 5 domains: irritability, agitation and crying; lethargy/social withdrawal; stereotypic behaviour; hyperactivity/noncompliance; inappropriate speech. It is useful to assess the possible effects of medications or other treatments. In particular is considered the Global score, obtained from the sum of the scores at each subscale (min: 0; max: 171; higher scores correspond to a greater level of behavioural problems). | Once at recruitment | |
Secondary | Total Raw score at the Social Communication Questionnaire - Current version(SCQ) | Children's communication, social and interpersonal skills are indirectly investigated through the Social Communication Questionnaire- Current version. It screens for characteristics associated with Autism (cut-off: 22) and Autism Spectrum Disorder (cut-off: 15) such as social interaction, communication and repetitive behaviour, considering the last three months (min: 0; max: 33). | Once at recruitment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05293184 -
The Global Angelman Syndrome Registry
|
||
Completed |
NCT00004351 -
Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes
|
N/A | |
Enrolling by invitation |
NCT06139172 -
Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities
|
N/A | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Recruiting |
NCT06229769 -
Natural History Study for Patients With Angelman Syndrome
|
||
Enrolling by invitation |
NCT03836300 -
Parent and Infant Inter(X)Action Intervention (PIXI)
|
N/A | |
Completed |
NCT03235037 -
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome
|
N/A | |
Recruiting |
NCT05100810 -
Angelman Syndrome Natural History Study-FAST UK
|
||
Completed |
NCT03644693 -
Nutritional Formulation for Angelman Syndrome
|
N/A | |
Completed |
NCT03358823 -
Study on the Brain Network of Angelman Syndrome
|
||
Recruiting |
NCT05945576 -
IDMet (RaDiCo Cohort) (RaDiCo-IDMet)
|
||
Completed |
NCT02670694 -
Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW
|
N/A | |
Recruiting |
NCT04768803 -
Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
|
||
Recruiting |
NCT05630066 -
Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
|
Phase 2 | |
Completed |
NCT00348933 -
Dietary Supplements for the Treatment of Angelman Syndrome
|
N/A | |
Recruiting |
NCT05011851 -
An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
|
Phase 2 | |
Terminated |
NCT03882918 -
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
|
Phase 3 | |
Completed |
NCT02996305 -
A Study in Adults and Adolescents With Angelman Syndrome (STARS)
|
Phase 2 | |
Completed |
NCT02056665 -
Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome
|
Phase 2 | |
Completed |
NCT01281475 -
A Trial of Levodopa in Angelman Syndrome
|
Phase 2/Phase 3 |